Latest news with #Sofosbuvir
Sky News AU
07-08-2025
- Health
- Sky News AU
A TikTok video revealing the cost of medicines in the US stuns Australians with many labelling American healthcare a 'scam'
A doctor has revealed the costs of different medications in Australia, the US and Scotland - leaving social media users flabbergasted at the US healthcare system. @drmichaelsays on Tiktok said the cost of a salbuthamol inhaler - commonly referred to as a blue inhaler - costs people in Scotland nothing, Australians $7AUD and people in the United States $77AUD. He showcased other medications that were either subsidised or free in Australia or Scotland in the viral video that has been seen over 2.7 million times. Another example is Atorvastatin, a medication that is used to lower cholesterol and prevent cardiovascular disease, which is priced at AU $6.70 or US$2,628 (AU$4032.67) and free in Scotland. He then discussed Sofosbuvir, which is used to treat hepatitis C. The medication can cost up to US$84,000 (AU$128,923.58) if a patient does not have insurance, whereas in Australia the cost is capped at AU$31.60 (US$20.61) - and has also been given out for free. 'Oh my god,' he said in reaction to the five-figure cost. 'See, in Scotland and Australia there's a socialist healthcare system which means that the government subsidises the cost of medications.' Commentators revealed that they were shocked about the cost, with many Australians revealing that they would rather deal with the high tax rate and subsidised medicine over the costs that American patients and consumers must contend with. 'Aussie here, happy to pay extra tax to know that everyone can get medical care. It's a human right,' one person said. Another said 'America is one gigantic scam,' while another felt that even though the Australian system is not perfect, they would have more rights in Australia. 'People in Australia cry over tax we have to pay,' added another. 'On the other hand, free hospitals, cheap medicine, cheap doctors, family tax benefit, aged care, unemployment benefits, aged pension, carer payments, maternity leave, farmhouse allowances, disability support, youth allowance. The list goes on. Australia looks after its citizens.' Healthcare in the United Kingdom is provided through the National Health Service, and responsibility for the management of the health service is delegated to the constituent nations of the UK, much like primary health is delegated to individual states and territories in Australia. The video comes as President Trump's administration seeks to impose tariffs on pharmaceutical companies that have not relocated their manufacturing base from overseas to the US. But Chief Economist at the Australia Institute Matt Grudnoff said even the president was unsure about imposing the tariffs, telling that politically, it could be a hard sell for Republican members of Congress heading into the midterms. 'If Trump imposes tariffs that increase the price of medicines in the US right before the midterm elections ... I can't see that happening for political reasons if nothing else,' he said. 'I think that Republicans facing re-election will be very keen for that not to happen and also Trump has been ... talking about decreasing medicine prices and (if) medicine prices go up, that might be quite difficult politically for him.' The Albanese government has stressed that in any tariff talks, the Pharmaceutical Benefits Scheme is not up for discussion, a position supported by the Coalition.
Time of India
05-08-2025
- Health
- Time of India
Medanta Appoints Dr. Pawan Rawal as Senior Director of Gastroenterology and Gastrosciences
New Delhi: Medanta – The Medicity has announced the appointment of Dr. Pawan Rawal as Senior Director, Gastroenterology and Gastrosciences . With over 18 years of experience in advanced gastroenterology and therapeutic endoscopy, Dr. Rawal is expected to contribute to the hospital's efforts in expanding specialised care in digestive and liver disorders. According to Medanta, Dr. Rawal brings expertise in managing complex pancreaticobiliary disorders , intestinal conditions, chronic liver diseases —including hepatitis B and C—and paediatric gastroenterology. His clinical practice includes advanced endoscopic procedures such as ERCP, EUS, and third-space endoscopy. He has also served as Principal Investigator in clinical trials, including India's launch study for Sofosbuvir, a treatment for hepatitis C. His research contributions have appeared in national and international peer-reviewed journals, and he is associated with various professional societies in the field of gastroenterology. An alumnus of PGIMER, Chandigarh, Dr. Rawal has previously worked at several healthcare institutions where he was involved in establishing endoscopy services and developing clinical pathways in hepatology and gastroenterology. His appointment is part of Medanta's broader focus on strengthening its super-specialty services and clinical leadership in gastrosciences.
Yahoo
12-02-2025
- Business
- Yahoo
Gilead (GILD) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Gilead Sciences (GILD) reported $7.57 billion in revenue for the quarter ended December 2024, representing a year-over-year increase of 6.4%. EPS of $1.90 for the same period compares to $1.72 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $7.06 billion, representing a surprise of +7.27%. The company delivered an EPS surprise of +13.77%, with the consensus EPS estimate being $1.67. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health. As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately. Here is how Gilead performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Product Sales- Veklury- U.S. $108 million versus the three-analyst average estimate of $160.11 million. The reported number represents a year-over-year change of -70.3%. Product Sales- Oncology- Trodelvy- U.S. $247 million versus $237.09 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +9.3% change. Product Sales- Liver Disease- Sofosbuvir / Velpatasvir- U.S. $185 million versus $202.61 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -14.4% change. Product Sales- HIV- Symtuza-Revenue share- U.S. $112 million versus the three-analyst average estimate of $109.94 million. The reported number represents a year-over-year change of +7.7%. Total product sales- Total: $7.54 billion versus $7.06 billion estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a +6.6% change. Revenues- Royalty contract and other revenues: $33 million versus the eight-analyst average estimate of $49.91 million. The reported number represents a year-over-year change of -26.7%. Product Sales- Oncology- Cell Therapy- Yescarta- Total: $390 million versus $386.44 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a +6% change. Product Sales- HIV- Biktarvy- Total: $3.77 billion versus the seven-analyst average estimate of $3.46 billion. The reported number represents a year-over-year change of +21.4%. Product Sales- HIV- Odefsey- Total: $336 million compared to the $314.11 million average estimate based on seven analysts. The reported number represents a change of -1.2% year over year. Product Sales- HIV- Genvoya- Total: $470 million versus the seven-analyst average estimate of $482.51 million. The reported number represents a year-over-year change of -9.1%. Product Sales- HIV- Descovy- Total: $616 million compared to the $573.59 million average estimate based on seven analysts. The reported number represents a change of +21% year over year. Product Sales- Oncology- Trodelvy- Total: $355 million versus the seven-analyst average estimate of $281.97 million. The reported number represents a year-over-year change of +18.7%. View all Key Company Metrics for Gilead here>>>Shares of Gilead have returned +6.2% over the past month versus the Zacks S&P 500 composite's +4.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report To read this article on click here. Zacks Investment Research
